Free Trial
NASDAQ:RGEN

Repligen (RGEN) Stock Price, News & Analysis

Repligen logo
$118.88 -1.61 (-1.34%)
Closing price 08/27/2025 04:00 PM Eastern
Extended Trading
$120.27 +1.39 (+1.17%)
As of 06:56 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Repligen Stock (NASDAQ:RGEN)

Key Stats

Today's Range
$118.83
$121.56
50-Day Range
$111.43
$134.00
52-Week Range
$102.96
$182.52
Volume
499,746 shs
Average Volume
785,214 shs
Market Capitalization
$6.69 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$169.45
Consensus Rating
Moderate Buy

Company Overview

Repligen Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
97th Percentile Overall Score

RGEN MarketRank™: 

Repligen scored higher than 97% of companies evaluated by MarketBeat, and ranked 40th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Repligen has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 8 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Repligen has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Repligen's stock forecast and price target.
  • Earnings Growth

    Earnings for Repligen are expected to grow by 37.21% in the coming year, from $1.72 to $2.36 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Repligen is -475.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Repligen is -475.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Growth Ratio

    Repligen has a PEG Ratio of 2.22. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Repligen has a P/B Ratio of 3.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Repligen's valuation and earnings.
  • Percentage of Shares Shorted

    6.84% of the float of Repligen has been sold short.
  • Short Interest Ratio / Days to Cover

    Repligen has a short interest ratio ("days to cover") of 4.4.
  • Change versus previous month

    Short interest in Repligen has recently increased by 7.06%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Repligen does not currently pay a dividend.

  • Dividend Growth

    Repligen does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.84% of the float of Repligen has been sold short.
  • Short Interest Ratio / Days to Cover

    Repligen has a short interest ratio ("days to cover") of 4.4.
  • Change versus previous month

    Short interest in Repligen has recently increased by 7.06%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Repligen has a news sentiment score of 1.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 16 news articles for Repligen this week, compared to 11 articles on an average week.
  • Search Interest

    4 people have searched for RGEN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Repligen insiders have bought more of their company's stock than they have sold. Specifically, they have bought $201,834.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 1.20% of the stock of Repligen is held by insiders.

  • Percentage Held by Institutions

    97.64% of the stock of Repligen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Repligen's insider trading history.
Receive RGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Repligen and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

RGEN Stock News Headlines

Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why
Imagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund. It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: "Brace yourselves. It's about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you." This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight.tc pixel
3 Unprofitable Stocks We Steer Clear Of
See More Headlines

RGEN Stock Analysis - Frequently Asked Questions

Repligen's stock was trading at $143.94 at the beginning of 2025. Since then, RGEN stock has decreased by 17.4% and is now trading at $118.88.

Repligen Corporation (NASDAQ:RGEN) released its earnings results on Tuesday, July, 29th. The biotechnology company reported $0.37 EPS for the quarter, missing the consensus estimate of $0.40 by $0.03. The business's quarterly revenue was up 14.8% compared to the same quarter last year.
Read the conference call transcript
.

The following companies are subsidiaries of Repligen: ARTeSYN Biosolutions Holdings Ireland Limite, Non-Metallic Solutions Inc, Engineered Molding Technology LLC, C Technologies Inc., Repligen Europe B.V., Repligen GmbH, Repligen India Private Limited, and others.

Repligen's top institutional shareholders include Champlain Investment Partners LLC (2.49%), Invesco Ltd. (2.45%), Sands Capital Management LLC (2.22%) and Brown Capital Management LLC (1.79%). Insiders that own company stock include Anthony Hunt, Karen A Dawes, Christine Gebski, Ralf Kuriyel, James Bylund, Martin D Madaus and Margaret Pax.
View institutional ownership trends
.

Shares of RGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Repligen investors own include NVIDIA (NVDA), Humana (HUM), Meta Platforms (META), Salesforce (CRM), CrowdStrike (CRWD), Broadcom (AVGO) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
7/29/2025
Today
8/27/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:RGEN
CIK
730272
Employees
1,778
Year Founded
1981

Price Target and Rating

High Price Target
$204.00
Low Price Target
$130.00
Potential Upside/Downside
+42.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.73
Research Coverage
11 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.25)
Trailing P/E Ratio
N/A
Forward P/E Ratio
69.12
P/E Growth
2.23
Net Income
-$25.51 million
Net Margins
-2.05%
Pretax Margin
-2.02%
Return on Equity
4.61%
Return on Assets
3.24%

Debt

Debt-to-Equity Ratio
0.26
Current Ratio
8.59
Quick Ratio
7.32

Sales & Book Value

Annual Sales
$673.96 million
Price / Sales
9.92
Cash Flow
$3.05 per share
Price / Cash Flow
39.03
Book Value
$36.65 per share
Price / Book
3.24

Miscellaneous

Outstanding Shares
56,258,000
Free Float
55,583,000
Market Cap
$6.69 billion
Optionable
Optionable
Beta
1.05

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:RGEN) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners